Citizens Financial Group Inc. RI Has $4.20 Million Holdings in Pfizer Inc. (NYSE:PFE)

Citizens Financial Group Inc. RI lifted its holdings in Pfizer Inc. (NYSE:PFE) by 40.7% during the 4th quarter, HoldingsChannel reports. The fund owned 145,969 shares of the biopharmaceutical company’s stock after acquiring an additional 42,202 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $4,202,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Adage Capital Partners GP L.L.C. grew its stake in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after buying an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC acquired a new stake in Pfizer during the fourth quarter worth about $255,000. Brookstone Capital Management grew its stake in Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after buying an additional 212,369 shares in the last quarter. ETF Store Inc. grew its stake in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after buying an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. grew its stake in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after buying an additional 74,487 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.6 %

NYSE PFE traded up $0.14 during trading hours on Friday, reaching $25.40. The company’s stock had a trading volume of 46,526,457 shares, compared to its average volume of 34,120,812. The firm has a fifty day simple moving average of $26.96 and a 200-day simple moving average of $28.42. The stock has a market cap of $143.83 billion, a P/E ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the business earned $1.14 EPS. Equities analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s payout ratio is 466.67%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PFE. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.